Global HIV control: is the glass half empty or half full?

Department of Epidemiology. Department of Infectious Diseases. Department of Microbiology and Center for Global Health. University of Pittsburgh School of Public Health, Pittsburgh, PA, USA / Department of Epidemiology and Department of International Health. Johns Hopkins Bloomberg School of Public Health. Johns Hopkins University of Baltimore. MD, USA / Department of Medicine. Division of Infectious Diseases. Stellenbosch University Faculty of Medicine and Health Sciences. Cape Town, South Africa.
Makerere University-Johns Hopkins University (MUJHU) Research Collaboration. Kampala, Uganda.
Fogarty International Center. US National Institutes of Health. Bethesda, MD, USA.
Department of Medicine. Division of HIV, Infectious Diseases and Global Medicine. University of California, San Francisco. San Francisco, USA.
Fundação Oswaldo Cruz. Instituto National de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Chelsea and Westminster Hospital National Health Service Foundation Trust. London, UK / Department of Clinical Research. London School of Hygiene & Tropical Medicine. London, UK.
School of Population and Public Health. University of British Columbia. Vancouver, BC, Canada.
Platform Life Sciences. Vancouver, BC, Canada.
Platform Life Sciences. Vancouver, BC, Canada / Department of Health Research Methods, Evidence and Impact. Faculty of Health Sciences. McMaster University. Hamilton, ON, Canada.
Department of Medicine. Section of Infectious Diseases. Yale School of Medicine. New Haven, CT, USA.
Division of Infectious Diseases. University of Pittsburgh School of Medicine. Pittsburgh, PA, USA.
Division of Infectious Diseases, Johns Hopkins School of Medicine; and Center for Global Health, Johns Hopkins University. Baltimore, MD, USA / Division of Intramural Research. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, MD, USA.

Abstract

The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally. Reduction in HIV incidence, however, has been unequal, with worsening epidemics in regions where the reach and scale of HIV control programmes have been insufficient, especially in eastern Europe, central Asia, the Middle East, north Africa, and Latin America where HIV epidemics are concentrated among key populations, including people who inject drugs, men who have sex with men, transgender people, and some minority racial and ethnic groups. The global state of the HIV pandemic highlights disparities in HIV control efforts and provides a roadmap for what should be done, including investment to better implement the effective HIV prevention and treatment tools that are available, but whose adoption and scale-up are not yet sufficient to get us close to an AIDS-free generation. To achieve the full potential of global HIV control, we call for urgent, evidence-informed implementation at scale of our existing and novel HIV prevention and treatment strategies in ways that are better, faster, more efficient, and cost-effective, especially in key populations and regions where the HIV pandemic continues to expand.

Keywords

HIV
Treatment and prevention
Global HIV control

Publisher

Elsevier

Citation

NACHEGA, Jean B. et al. Global HIV control: is the glass half empty or half full? The Lancet, v. 10, p. 617-622, Sept. 2023.

DOI

10.1016/S2352-3018(23)00150-9

ISSN

2405-4704

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/61940

Type

Copyright

Restricted access

Embargo date

2030-12-31

Collections

Share

Statistics

Metadata

Author

Affilliation